Description
Vortisign (Vortioxetine) 10 mg
Vortisign 10 mg is a brand name for vortioxetine, an oral antidepressant used for the treatment of major depressive disorder in adults. The verified product name and strength support identification as a vortioxetine tablet presentation, but brand availability and local regulatory status may vary by country.
Active Ingredient and Medicine Class
The active ingredient is vortioxetine. It is a multimodal antidepressant and serotonin reuptake inhibitor with activity at several serotonin receptors. Regulatory sources classify it as an antidepressant medicine for depressive disorder.
Established Medical Uses
Vortioxetine is established for the treatment of major depressive disorder in adults. European and U.S. prescribing information describe this as its approved therapeutic use.
How It Works
Vortioxetine acts on serotonin pathways in more than one way. It inhibits the serotonin transporter and also interacts with several serotonin receptor subtypes, which may contribute to its antidepressant effects. Human review literature describes this as a multimodal mechanism rather than a single-action SSRI effect.
Important Safety Information
Vortioxetine is contraindicated in people with hypersensitivity to vortioxetine or any component of the formulation, and it must not be used with MAO inhibitors intended to treat psychiatric disorders, or within the required washout periods because of the risk of serotonin syndrome. Prescribing information also warns about suicidal thoughts and behaviours in children, adolescents, and young adults, activation of mania or hypomania, angle-closure glaucoma, and hyponatremia. Clinically significant interactions include drugs that increase serotonin toxicity risk, strong CYP2D6 inhibitors, and strong CYP inducers.
Possible Side Effects
Common adverse effects reported in clinical studies include nausea, constipation, and vomiting. Other recognised effects include sexual dysfunction, dizziness, and discontinuation symptoms such as headache or muscle tension after stopping higher doses. Serious but less common reactions can include serotonin syndrome, hypersensitivity reactions, and mood switching to mania or hypomania.
Scientific Evidence
Peer-reviewed reviews and meta-analyses in PubMed support vortioxetine as an effective antidepressant for adults with major depressive disorder, with an overall tolerability profile that is broadly consistent with other antidepressants. Some reviews report potential benefits on cognitive symptoms in depressed patients, but these findings should be interpreted as clinical research findings rather than guaranteed individual benefit.
Medical Information Notice
This summary is provided for educational purposes only and is based on sources available at the time of review. It does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA) — Brintellix (vortioxetine) EPAR
- DailyMed / U.S. prescribing information — TRINTELLIX (vortioxetine) tablets, Full Prescribing Information
- Garnock-Jones K. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs. 2014. PubMed article
